Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?

European Urology

Volumn 54, Issue 3, 2008, Pages 489-492

  Margulis, Vitaly ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR THERAPY AGENT; SUNITINIB;

ANGIOGENESIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE DURATION; EDITORIAL; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MOLECULAR THERAPY; NEPHRECTOMY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SYSTEMIC THERAPY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEPHRECTOMY; PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; PYRROLES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44649097718     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.12.041     Document Type: Editorial

References (18)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
3. Dekernion J.B., Ramming K.P., and Smith R.B. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120 (1978) 148-152
4. Montie J.E., Stewart B.H., Straffon R.A., et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117 (1977) 272-275
5. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
6. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
7. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
8. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
9. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
10. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
11. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
12. Vieweg J., Su Z., Dahm P., and Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 13 (2007) 727s-732s
13. Wood C.G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13 (2007) 697s-702s
14. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 7 (2007) 73-78
15. Howdieshell T.R., Callaway D., Webb W.L., et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96 (2001) 173-182
16. Roman C.D., Choy H., Nanney L., et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105 (2002) 43-47
17. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
18. Kesmodel SB, Ellis LM, Lin E, et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer liver metastases. ASCO Abstract. 2007, abstract no. 234.